AdvisorNet Financial Inc Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AdvisorNet Financial Inc cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 78 shares of the biopharmaceutical company’s stock after selling 22 shares during the quarter. AdvisorNet Financial Inc’s holdings in Regeneron Pharmaceuticals were worth $56,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $37,000. Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $39,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $42,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $681.58 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market cap of $74.90 billion, a P/E ratio of 16.87, a P/E/G ratio of 1.60 and a beta of 0.10. The firm has a 50 day simple moving average of $738.60 and a 200 day simple moving average of $949.99. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20.

Analyst Ratings Changes

A number of research analysts have commented on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Oppenheimer lowered their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.